New Phase 3 data with aprocitentan to be presented at the European Society of Hypertension Annual Meeting 202
Allschwil, Switzerland – June 23, 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the